Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2013 12:15 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Awarded a NIH/NIDDK SBIR Fast Track Grant to Advance its Glucagon Mini-Dose Pen for Treatment of Mild to Moderate Hypoglycemia

AUSTIN, Texas, Sept. 23, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, biopharmaceutical company developing patient-friendly injectable treatments for diabetes and...
June 21, 2013 10:00 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Presents Non-Aqueous Glucagon Stability Data at the American Diabetes Association 73nd Scientific Sessions

Austin, TX, June 21, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that it is presenting at the American Diabetes Association 73nd Scientific Sessions in Chicago, IL...
April 17, 2013 11:39 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Awarded Phase II Funding of NIH Fast -Track SBIR Grant to Advance Glucagon for the Artificial Pancreas

Austin, TX, April 17, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, pharmaceutical company developing patient-friendly injectable treatments for diabetes and other...
February 11, 2013 09:42 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Closed 2012 with $6M In Additional Funding

Austin, TX, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging pharmaceutical company developing patient-friendly injectable treatments for diabetes,...
July 31, 2012 10:41 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Bi-Hormonal Artificial Pancreas

Austin, TX, July 31, 2012 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments for diabetes...
March 20, 2012 11:18 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Receives U.S. Patent for Injection of Ultra-Concentrated Drugs and Biologics

Austin, TX, March 20, 2012 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that is has been granted U.S. Patent No. 8,110,209, "Intracutaneous Injection," modernizing drug...

keyboard_arrow_left Previous Page